Severity of depression and response to antidepressants: GENPOD randomised controlled trial

British Journal of Psychiatry

Volumn 200, Issue 2, 2012, Pages 130-136

  Wiles, Nicola J ^a   Mulligan, Jean ^a   Peters, Tim J ^a   Cowen, Philip J ^b   Mason, Victoria ^c   Nutt, David ^d   Sharp, Deborah ^a   Tallon, Debbie ^a   Thomas, Laura ^a   O'Donovan, Michael C ^e   Lewis, Glyn ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF WORCESTER   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOMATION; BECK DEPRESSION INVENTORY; COMPARATIVE STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EMPLOYMENT STATUS; FEMALE; FOLLOW UP; HUMAN; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SOCIAL SUPPORT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; GREAT BRITAIN; HUMANS; INTENTION TO TREAT ANALYSIS; INTERNATIONAL CLASSIFICATION OF DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; MORPHOLINES; PRIMARY HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857074763     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.091223     Document Type: Article

References (38)

1. Prescribing Support Unit. Prescribing Monitoring Report April 2007-March 2008. Information Centre for Health and Social Care, 2008.
2. McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME. Recent trends in the use of antidepressant drugs in Australia. Med J Aust 2000; 173: 458-61.
3. Pincus HA, Tanielian TL, Marcus SC, Olfon M, Zarin DA, Thompson J, et al. Prescribing trends in psychotropic medications. JAMA 1998; 279: 526-31.
4. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurmentbased care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
5. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-93. (Pubitemid 46505879)
6. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 2000; 177: 292-302.
7. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
8. Eyding D, Leigemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010; 341: c4737.
9. Papakostas GI, Nelson JC, Kasper S, Moller H-J. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 122-7. (Pubitemid 350296847)
10. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45.
11. Massana J, Moller H-J, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depression. Int Clin Psychopharmacol 1999; 14: 73-80. (Pubitemid 29149865)
12. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000; 15: 279-89. (Pubitemid 30660963)
13. Brown WA, Dornseif BE, Wernicke JF. Placebo response in depression: a search for predictors. Psychiatry Res 1988; 26: 259-64. (Pubitemid 19021044)
14. Uher R, Maier W, Hauser J, Marušič A, Schmael C, Mors O, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009; 194: 252-9.
15. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response. Arch Gen Psychiatry 1976; 33: 1479-89.
16. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
17. Lewis G, Mulligan J, Wiles N, Cowen PJ, Craddock N, Ikeda M, et al. Polymorphisms of the 5-HT transporter and response to antidepresants: randomised controlled trial. Br J Psychiatry 2011; 198: 464-71.
18. Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen PJ, et al. Genetic and clinical predictors of treatment response in depression: the GENPOD randomised trial protocol. Trials 2008; 9: 29.
19. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
20. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol Med 1992; 22: 465-86.
21. Lewis G. Assessing psychiatric disorder with a human interviewer or a computer. J Epidemiol Community Health 1994; 48: 207-10. (Pubitemid 24148410)
22. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
23. Beck A, Steer RA, Brown GK. Beck Depression Inventory (2nd edn). The Psychological Corporation, 1996.
24. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry 2001; 158: 1843-9. (Pubitemid 33054777)
25. Hill SA, Taylor MJ, Harmer CJ, Cowen PJ. Acute reboxetine administration increases plasma and salivary cortisol. J Psychopharmacol (Oxf) 2003; 17: 273-5. (Pubitemid 37150835)
26. Szabadi E, Bradshaw CM, Boston PF, Langley RW. The human pharmacology of reboxetine. Hum Psychopharmacol 1998; 13 (suppl 1): S3-12.
27. Jenkinson C, Layte R. Development and testing of the UK SF-12 (Short Form Health Survey). J Health Serv Res Policy 1997; 2: 14-8. (Pubitemid 27077648)
28. Zigmond AS, Snaith RP. The Hospital Anxiety And Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70. (Pubitemid 13098606)
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
30. Carpenter J, Kenward M. Guidelines for Handling Missing Data in Social Science Research. London School of Hygiene and Tropical Medicine, no date (http://missingdata.lshtm.ac.uk/downloads/guidelines.pdf).
31. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994; 9 (suppl 1): 35-40. (Pubitemid 24107715)
32. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, et al. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: Kinetic studies with the ALI/VFL-SI/TT mutant. Neurosci Lett 2009; 462: 207-12.
33. Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. BMJ 2000; 321: 1383-8.
34. Kessler D, Lewis G, Kaur S, Wiles N, King M, Weich S, et al. Therapistdelivered internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet 2009; 374: 628-34.
35. Hotopf M, Sharp D, Lewis G. What's in a name? A comparison of four psychiatric assessments. Soc Psychiatry Psychiatr Epidemiol 1998; 33: 27-31. (Pubitemid 28080710)
36. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005; 62: 409-16. (Pubitemid 40471690)
37. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-8.
38. Fischer K, Goetghebeur E, Vrijens B, White IR. A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments. Biostatistics 2010; 12: 247-57.